BACKGROUND

Fingolimod is an effective treatment for active relapsing-remitting multiple sclerosis (MS). Discontinuation of therapy may be followed by recurrence of disease activity. Thus, female MS patients may be at risk of relapse during pregnancy after stopping fingolimod.

OBJECTIVES AND METHODS

To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy.

RESULTS

All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod.

CONCLUSION

The risk of recurrence of disease activity during pregnancy after stopping fingolimod may be substantial. This should be considered and discussed with MS patients who are planning to become pregnant.